GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » Short-Term Debt

Exact Therapeutics AS (OSL:EXTX) Short-Term Debt : kr0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Exact Therapeutics AS Short-Term Debt?

Exact Therapeutics AS's Short-Term Debt for the quarter that ended in Dec. 2023 was kr0.00 Mil.


Exact Therapeutics AS Short-Term Debt Historical Data

The historical data trend for Exact Therapeutics AS's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Therapeutics AS Short-Term Debt Chart

Exact Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial - - - - -

Exact Therapeutics AS Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Exact Therapeutics AS Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Exact Therapeutics AS Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Exact Therapeutics AS's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Therapeutics AS (OSL:EXTX) Business Description

Traded in Other Exchanges
N/A
Address
Ostre Aker vei 19, Oslo, NOR, 0581
Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing a technology platform for therapeutic enhancement - Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Exact Therapeutics AS (OSL:EXTX) Headlines

No Headlines